Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q1 FY24 Earnings Presentation
23 slides from Healthcare Global Enterprises's earnings presentation, Aug 10, 2023
Slide 1: Stock exchange cover letter: Investor Presentation
August 10, 2023 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, S
Slide 2: Healthcare Global Enterprises Limited Investor Presentation August 2023
HEALTHCARE GLOBAL ENTERPRISES LIMITED I NV ESTOR P R ESENTATI ON August 2023
Slide 3: Safe Harbor
SAFE HARBOR This presentation and its contents are confidential and are not for release, publication or distribution, in whole or in part, directly or indirectly, in or into or from the United States of America, Canada, Australia, Japan or any jurisdiction where such distribution is unlawful. This p
Slide 4: Q1FY24 Financial & Operational Highlights
Q1FY24 FINANCIAL & SUBASENI LENKA, CANCER WINNER OPERATIONAL HIGHLIGHTS I am eternally thankful to Dr. Panda and other specialists at HCG Panda Cancer Hospital, as the specialists were able to treat my condition the right way, the first time 3 www. h c g e l . c o m
Slide 5: Acquisition 1: HCG NCHRI, Nagpur
Acquisition 1: HCG NCHRI, Nagpur About HCG NCHRI ❖ HCG NCHRI LLP operates and manages 115 bedded hospital in Nagpur, providing comprehensive cancer care services under medical services agreement ❖ Revenue from operations of HCG NCHRI LLP for the financial year ended March 31, 2023, was INR 51.4 Cror
Slide 6: Acquisition 2: SRJ CBCC Hospital, Indore
Acquisition 2: SRJ CBCC Hospital, Indore Asset Overview • Indore based Comprehensive Cancer Care (CCC) hospital • 50 beds facility offering Medical, Surgical and Radiation oncology • First & #1 Comprehensive Cancer Center in private space in Indore • To acquire 100% of hospital on a slump sale basis
Slide 7: Leveraging a successful playbook of smart acquisitions and driving sustained growth
Le v e r aging a s uc c essf u l p la y b ook of s ma r t a c q u is it ions a nd d r iv ing s u s t a ine d gr ow t h p os t a c q u is it ion Time tested and highly replicable model of consistent revenue growth across geographies HCG Ahmedabad HCG Cuttack HCG Vijayawada HCG Nashik Acquisition 2013
Slide 8: Clinical Highlights & Recognitions
Clinical Highlights & Recognitions Noteworthy Clinical Achievements ❖ Dr Joydeep Chakrabartty, Senior Consultant, BMT & Haematology, HCG Kolkata was selected as the Country Advisor for East India by the Royal College of Pathologists ❖ Dr Nishit Ojha, Dr Amey Panchal (Fellows in BMT & Haematology) &
Slide 9: Financial Highlights Q1 FY24
Financial Highlights Q1 FY24 REVENUE R E V E N U E - H C G C e n t e r s (1) REVENUE - Milann Centers +13% +14% -5% 4,607 4,443 173 164 4,081 3,908 Q1FY23 Q1FY24 Q1 FY23 Q1 FY24 Q1FY23 Q1FY24 PROFIT AFTER TAX PROFIT AFTER TAX EBITDA* EBITDA* MARGIN (Pre-IND AS) (Post-IND AS) # Proforma +5% EBIDTA -
Slide 10: Improved Performance Leading to Profitability
Improved Performance Leading to Profitability 2.2x 4081 4200 4247 4417.1 4,607 3231 3520 3581 3646 Revenue 2479 2740 2981 (INR mn) 1935 Q1'21 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q3'22 Q4'22 Q1'23 Q2'23 Q3'23 Q4'23 Q1'24 3.8x EBITDA (Excl. 306 744 760 773 778 764 200 632 636 652 ESOP) 488 383 396 (INR mn)
Slide 11: Growth Across HCG Centers
Growth Across HCG Centers* Matured Centers Emerging Centers^ ~1.4x g r o w t h i n l a s t 9 q u a r t e r s ~1.7x g r o w t h i n l a s t 9 q u a r t e r s +11% +22% REVENUE# 3,169 3,314 1,090 1,129 2,979 3,090 3,065 1,015 2,596 2,628 2,663 929 945 2,418 785 826 693 750 Q1FY22 Q2FY22 Q3FY22 Q4FY22
Slide 12: Strong Operating Metrics with Significant Capacity Headroom
Strong Operating Metrics with Significant Capacity Headroom Key Driver Metric Indicator % Revenue Q1’23 Q4’23 Q1’24 14% 92 95 105 Lead indicator of Volume Growth; key OPD Footfall (‘000) operating metric tracked by HCG; has 19%* correlation to OPD Footfalls 9% 32 34 35 Key indicator for Medical Onco
Slide 13: HCG – Q1FY24 Operational Metrics
HCG – Q1FY24 Operational Metrics # MATURED CENTERS EMERGING CENTERS MATURED CENTERS TOTAL AOR (%) AOR (%) A O R ^* ( % ) ROCE (%) 66.9% 67.1% 66.4% 20.2% 61.0% in Q1FY23 61.7% in Q1FY23 59.4% in Q1FY23 19% in Q1FY23 590 bps 540 bps 700 bps 120 bps ROCE pre-corporate a l l o ca t i o n s s ta n d s a
Slide 14: HCG – Cluster Wise Revenue Break Up
HCG – Cluster Wise Revenue Break Up # C LU ST E R Q1FY24 Q1FY23 Y-o-Y Q4FY23 Q-o-Q K A R N ATA K A 1,504 1,373 10% 1,498 - G U J A R AT 1,136 1,001 14% 1,084 5% MAHARASHTRA 659 600 10% 627 5% EAST INDIA 487 387 26% 479 2% ANDHRA PRADESH 334 297 13% 289 16% TA M I L N A D U 76 60 27% 73 4% NORTH INDI
Slide 15: Milann – Implementing Strategic Initiatives
Milann – Implementing Strategic Initiatives BENGALURU (5 Centers) Growth Growth Particulars Q1FY24 Q1FY23 Q4FY23 Y-o-Y Q-o-Q New Registrations 1,212 1,612 -24.8% 1,286 -5.8% M S Ramaiah Nagar Shivananda IVF Cycles 414 538 -23.0% 461 -10.2% Indiranagar Revenues Whitefield 164 173 -5.1% 158 3.8% (Rs.
Slide 16: Capital Expenditure & Net Debt
Capital Expenditure & Net Debt CAPITAL EXPENDITURE (Rs. Mn.) NET DEBT (Rs. Mn.) NET DEBT 30 th June 2023 31 st March 2023 HCG CENTERS Q1FY24 Q1FY23 Bank Debt ( 1) 3,462 3,733 Vendor Finance ( 2) 321 223 Matured Centers 326 122 Other Debt 6 8 Less: Cash & Cash Equivalents ( 3) 1,623 1,983 Emerging Ce
Slide 17: Q1 FY24 Consolidated Profit & Loss Account
Q1 FY24 Consolidated Profit & Loss Account Profit and Loss (in Rs. Mn.) Q1 FY24 Q1 FY23 Y-o-Y Q4 FY23 Q-o-Q Revenues from Operations 4,597.1 4,073.1 4,409.8 Income from Govt. Grant 9.7 7.4 7.3 Total Revenue from Operations 4,606.8 4,080.5 12.9% 4,417.1 4.3% Cost of Goods Sold 1,179.1 978.0 1,164.0 E
Slide 18: Historical Financial Highlights
HISTORICAL FINANCIAL SHANKAR, CANCER WINNER HIGHLIGHTS The days I was at HCG, I felt like I was sleeping at home. They never stop caring for you. The doctors and nurses are always finding ways to make this difficult journey as comfortable as possible 17 www. h c g e l . c o m
Slide 19: Historical Profit & Loss Account
Historical Profit & Loss Account Profit and Loss (in Rs. Mn.) FY23 FY22 FY21 FY20 FY19 CAGR Revenues from Operations 16,914 13,948 10,092 10,923 9,760 Income from Govt. Grant 30 30 43 33 27 Total Revenue from Operations 16,944 13,978 10,134 10,956 9,787 15% Costs of Goods Sold 4,241 3,549 3,632 3,64
Slide 20: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Equity & Liabilities (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 1,391 1,390 1,254 887 879 Other Equity 7,214 7,313 5,718 2,926 3,933 Equity Attributable To Equity Holders Of The Company 8,605 8,703 6,972 3,813 4,811 Non-Controlling I
Slide 21: Historical Balance Sheet
Historical Balance Sheet Balance Sheet - Assets (in Rs. Mn.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, Plant And Equipment 9,718 9,315 8,531 9,271 8,026 Capital Work in Progress 182 217 300 461 1,440 Rights-of-use Assets 3,813 4,045 4,114 5,776 0 Goodwill 1,812 1,813 963 1,093
Slide 22: Historical Cash Flow Statement
Historical Cash Flow Statement Cash Flow Statement (in Rs. Mn) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Net Profit Before Tax 449 878 -2,287 -1,193 -334 Adjustments For: Non - Cash Items / Other Investment Or Financial 2,753 1,666 3,619 2,988 2,463 Items Operating Profit Before Working Capital Changes 3,2
Slide 23: Thank You
THANK YOU Company: HealthCare Global Enterprises Limited Investor Relation Advisors: Strategic Growth Advisors CIN: L15200KA1998PLC023489 CIN: U74140MH2010PTC204285 For updates and specific queries, please visit Mr. Sagar Shroff / Mr. Ayush Haria www.hcgoncology.com sagar.shroff@sgapl.net / ayush.ha
HealthCare Global Enterprises — Q1 FY24 Earnings Presentation on 6ix